FDA · FDA approves Hibsago, a hepatitis B drug that lets some patients stop treatment
In two trials, 24% of patients on Hibsago qualified to stop their hepatitis B medicine. None of the patients on placebo did.
Lead story
FDA · Top Stories
CMSAEP 2027 scorecard: more members in 4-star plans, fewer counties for some big insurers
Oscar HealthOscar grows its county count 24% as ACA insurers set 2027 plans
NovoCare (Novo Nordisk)How drugmakers and wearables are reaching patients directly
- WWolters KluwerDoximity adds UpToDate to its AI tool, days after its OpenEvidence lawsuit ended
By section
More stories
Judi HealthJudi Health gets a CMS contract for its own employer retiree Part D plan
OuraOura adds Cardio Effort and automatic VO2 max to its ring
PacBioPacBio and Verily team up to pair long-read genomes with clinical data- CMSCMS proposes MA directory checks and PBM pay rules
Nextgov/FCWCMS official says parts of the WISeR AI prior auth test are not working
PBSMedicare open enrollment opens with Part D changes
GoogleGoogle Health's data deals and Medicare's rules
Newsletter
The week in health tech, in five minutes.
The health tech news that matters, every morning. What changed, the number, and the link. Free, weekly, by email.